Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.16
BAYRY's Cash to Debt is ranked lower than
52% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. BAYRY: 0.16 )
BAYRY' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.16

Equity to Asset 0.36
BAYRY's Equity to Asset is ranked higher than
52% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. BAYRY: 0.36 )
BAYRY' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.46
Current: 0.36

0.21
0.46
F-Score: 6
Z-Score: 2.64
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.23
BAYRY's Operating margin (%) is ranked higher than
80% of the 787 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. BAYRY: 12.23 )
BAYRY' s 10-Year Operating margin (%) Range
Min: -4.21   Max: 12.29
Current: 12.23

-4.21
12.29
Net-margin (%) 8.79
BAYRY's Net-margin (%) is ranked higher than
80% of the 787 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.39 vs. BAYRY: 8.79 )
BAYRY' s 10-Year Net-margin (%) Range
Min: -4.41   Max: 14.56
Current: 8.79

-4.41
14.56
ROE (%) 17.63
BAYRY's ROE (%) is ranked higher than
93% of the 796 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. BAYRY: 17.63 )
BAYRY' s 10-Year ROE (%) Range
Min: -9.14   Max: 31.97
Current: 17.63

-9.14
31.97
ROA (%) 6.65
BAYRY's ROA (%) is ranked higher than
83% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. BAYRY: 6.65 )
BAYRY' s 10-Year ROA (%) Range
Min: -3.18   Max: 8.79
Current: 6.65

-3.18
8.79
ROC (Joel Greenblatt) (%) 31.03
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. BAYRY: 31.03 )
BAYRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.12   Max: 34.99
Current: 31.03

-6.12
34.99
Revenue Growth (%) 4.60
BAYRY's Revenue Growth (%) is ranked higher than
68% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. BAYRY: 4.60 )
BAYRY' s 10-Year Revenue Growth (%) Range
Min: -10.6   Max: 14
Current: 4.6

-10.6
14
EBITDA Growth (%) 2.40
BAYRY's EBITDA Growth (%) is ranked higher than
69% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. BAYRY: 2.40 )
BAYRY' s 10-Year EBITDA Growth (%) Range
Min: -17.7   Max: 18.3
Current: 2.4

-17.7
18.3
EPS Growth (%) 35.00
BAYRY's EPS Growth (%) is ranked higher than
91% of the 627 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. BAYRY: 35.00 )
BAYRY' s 10-Year EPS Growth (%) Range
Min: -19.1   Max: 41.4
Current: 35

-19.1
41.4
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BAYRY Guru Trades in Q3 2013

Ken Fisher 86,861 sh (+2.85%)
» More
Q4 2013

BAYRY Guru Trades in Q4 2013

Ken Fisher 85,386 sh (-1.7%)
» More
Q1 2014

BAYRY Guru Trades in Q1 2014

Ken Fisher 270,713 sh (+217.05%)
» More
Q2 2014

BAYRY Guru Trades in Q2 2014

Ken Fisher 2,302,369 sh (+750.48%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-06-30 Add 750.48%0.6%$126.84 - $144.81 $ 135-2%2302369
Ken Fisher 2014-03-31 Add 217.05%0.06%$128.3 - $142.7 $ 1350%270713
Ken Fisher 2013-06-30 Add 34.62%0.01%$101 - $112.75 $ 13526%84456
Vanguard Health Care Fund 2012-12-31 Reduce -21.2%0.21%$83.28 - $96.38 $ 13551%2044656
Ken Fisher 2012-09-30 New Buy0.02%$68.01 - $88.62 $ 13575%72838
Ken Fisher 2012-03-31 Sold Out 0.01%$0.04 - $75.15 $ 135125%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.40
BAYRY's P/E(ttm) is ranked higher than
84% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.30 vs. BAYRY: 24.40 )
BAYRY' s 10-Year P/E(ttm) Range
Min: 8.67   Max: 36.88
Current: 24.4

8.67
36.88
P/B 4.45
BAYRY's P/B is ranked higher than
57% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. BAYRY: 4.45 )
BAYRY' s 10-Year P/B Range
Min: 1.15   Max: 4.75
Current: 4.45

1.15
4.75
P/S 2.18
BAYRY's P/S is ranked higher than
79% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. BAYRY: 2.18 )
BAYRY' s 10-Year P/S Range
Min: 0.45   Max: 2.29
Current: 2.18

0.45
2.29
PFCF 29.99
BAYRY's PFCF is ranked higher than
86% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BAYRY: 29.99 )
BAYRY' s 10-Year PFCF Range
Min: 7.28   Max: 107
Current: 29.99

7.28
107
EV-to-EBIT 18.81
BAYRY's EV-to-EBIT is ranked higher than
85% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.86 vs. BAYRY: 18.81 )
BAYRY' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 24.6
Current: 18.81

7.2
24.6
PEG 9.04
BAYRY's PEG is ranked higher than
83% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BAYRY: 9.04 )
BAYRY' s 10-Year PEG Range
Min: 1.54   Max: 9.76
Current: 9.04

1.54
9.76
Shiller P/E 36.67
BAYRY's Shiller P/E is ranked higher than
77% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 96.41 vs. BAYRY: 36.67 )
BAYRY' s 10-Year Shiller P/E Range
Min: 13.45   Max: 50.98
Current: 36.67

13.45
50.98
Current Ratio 1.43
BAYRY's Current Ratio is ranked higher than
58% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. BAYRY: 1.43 )
BAYRY' s 10-Year Current Ratio Range
Min: 1   Max: 2.13
Current: 1.43

1
2.13
Quick Ratio 0.93
BAYRY's Quick Ratio is ranked higher than
55% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. BAYRY: 0.93 )
BAYRY' s 10-Year Quick Ratio Range
Min: 0.64   Max: 1.44
Current: 0.93

0.64
1.44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.56
BAYRY's Dividend Yield is ranked higher than
75% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. BAYRY: 1.56 )
BAYRY' s 10-Year Dividend Yield Range
Min: 1.87   Max: 3.93
Current: 1.56

1.87
3.93
Dividend Payout 0.35
BAYRY's Dividend Payout is ranked higher than
79% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. BAYRY: 0.35 )
BAYRY' s 10-Year Dividend Payout Range
Min: 1.23   Max: 2.1
Current: 0.35

1.23
2.1
Dividend growth (3y) -100.00
BAYRY's Dividend growth (3y) is ranked higher than
61% of the 360 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. BAYRY: -100.00 )
BAYRY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -4.6
Current: -100

Yield on cost (5-Year) 1.60
BAYRY's Yield on cost (5-Year) is ranked higher than
69% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. BAYRY: 1.60 )
BAYRY' s 10-Year Yield on cost (5-Year) Range
Min: 1.87   Max: 3.93
Current: 1.6

1.87
3.93

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.58
BAYRY's Price/DCF (Projected) is ranked higher than
90% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.00 vs. BAYRY: 1.58 )
BAYRY' s 10-Year Price/DCF (Projected) Range
Min: 0.67   Max: 2.26
Current: 1.58

0.67
2.26
Price/Median PS Value 1.75
BAYRY's Price/Median PS Value is ranked higher than
61% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. BAYRY: 1.75 )
BAYRY' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 3.73
Current: 1.75

0.26
3.73
Price/Peter Lynch Fair Value 4.33
BAYRY's Price/Peter Lynch Fair Value is ranked higher than
86% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BAYRY: 4.33 )
BAYRY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.12   Max: 5.64
Current: 4.33

1.12
5.64
Earnings Yield (Greenblatt) 5.30
BAYRY's Earnings Yield (Greenblatt) is ranked higher than
76% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. BAYRY: 5.30 )
BAYRY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 13.9
Current: 5.3

4.1
13.9
Forward Rate of Return (Yacktman) 8.84
BAYRY's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BAYRY: 8.84 )
BAYRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.1   Max: 18.3
Current: 8.84

-10.1
18.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAYN.Germany, BAYA.Germany, BAY.Italy, BAY.Spain, BAYN N.Mexico
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products (46% of sales), material sciences (36% of sales), and crop sciences (18% of sales). Bayer's over-the-counter health-care product division is the third-largest in the world.
» More Articles for OTCPK:BAYRY

Headlines

Articles On GuruFocus.com
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Ken Fisher for Forbes - 5 Fantastic Stocks for Fretters Jun 26 2013 
Pfizer: A Strong Stock for 2013 Apr 20 2012 
Maxygen Inc. (MAXY): A Magic Formula Stock to Avoid Feb 05 2009 

More From Other Websites
Not intended for U.S. and UK Media -- Bayer Forms Alliance with Kyoto University in Japan --... Oct 24 2014
Bayer once again included in CDP Climate Performance Leadership Index: -- Bayer rated international... Oct 16 2014
Break Up Bonanza Rolls On With Hewlett-Packard, EBay Oct 09 2014
Regeneron's Eye Drug Eylea Wins Another FDA Approval Oct 07 2014
Bayer/Regeneron Successfully Expand Eylea Label in Japan Sep 23 2014
The Zacks Analyst Blog Highlights: Las Vegas Sands, MGM Resorts International, Melco Crown... Sep 22 2014
Bayer to Shed MaterialScience Business, Shares Rise Sep 19 2014
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 Sep 18 2014
Bayer to split off polymer division with IPO Sep 18 2014
Bayer to split off polymer division with IPO Sep 18 2014
Why Bayer (BAYRY) Stock Is Surging Today Sep 18 2014
Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Sep 12 2014
Bayer Presents Positive Long-Term Results on Adempas Sep 09 2014
OncoMed's Shares Gain on Lifting of Partial Clinical Hold Sep 08 2014
Bayer/Regeneron Looking for Eylea Label Expansion in Japan Sep 08 2014
The Zacks Analyst Blog Highlights: Intel, Advanced Micro Devices, Johnson & Johnson, Bayer and... Sep 08 2014
Bayer Discloses Encouraging Data on Anticoagulant Xarelto Sep 03 2014
Bayer/Johnson & Johnson to Expand Xarelto Label Further Sep 02 2014
OncoMed's Vantictumab Studies' Partial Clinical Hold Lifted Aug 29 2014
Return to Behemoth Stocks Aug 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK